CHMP recommends pirtobrutinib for relapsed or refractory CLL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of pirtobrutinib for the
Chronic Lymphocytic Leukemia
News
Lymphoma
Aggressive B-Cell Lymphomas
Is CAR-T feasible in elderly patients with B-cell lymphoma?
Octogenarians with B-cell lymphoma may be considered for chimeric antigen receptor (CAR) T-cell treatment, according to a study led by Mohamed A. Kharfan-Dabaja,
Lymphoma
Potential risk of lymphoma in individuals with large tattoos
Individuals with tattoos, particularly larger ones, may have an increased risk of lymphoma and skin cancer, according to a recent study. “We are
Leukemia
Lymphoma
Multiple Myeloma
News
Is it time to revisit MRD’s role in relapse detection?
A Viewpoints article published in The Lancet Haematology, calls for further research into the use of measurable residual disease (MRD) in hematologic malignancies.
Myeloproliferative Neoplasms
Polycythemia Vera
News
ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera
The Brazilian Health Regulatory Agency (ANVISA) has approved ropeginterferon alfa-2b (BESREMi) for the treatment of adult patients with polycythemia vera (PV).
News
Society Updates
SOHO launches new fundraising initiative
SOHO is launching a special fundraising initiative now through its Thirteenth Annual Meeting in Houston, Texas, taking place between September 3 and 6,
Multiple Myeloma
China NMPA approves IND for KPG-818 in relapsed or refractory MM
The Center for Drug Evaluation of the China National Medical Products Administration (NMPA) approved the IND application for KPG-818.
Lymphoma
T-Cell Lymphoma
FDA clears linperlisib for phase 3 trial in relapsed/refractory PTCL
The US Food and Drug Administration (FDA) has approved the design of a global phase 3 trial for linperlisib for the treatment of
Acute Lymphoblastic Leukemia
News
Nanobody-based CD7 CAR-T induces responses in patients with AML in early-phase study
A phase 1 study found that “naturally selected” CD7 chimeric antigen receptor T-cell (NS7CAR-T) therapy was well-tolerated and induced complete responses (CRs) in
Society Updates
Ask the lymphoma expert: Dr. Maddocks
Have a burning question about a patient with B-cell malignancies for Hodgkin or non-Hodgkin lymphoma? Ask Kami Maddocks, MD, professor in the College